Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Mithra Pharmaceuticals S.A.
  6. News
  7. Summary
    MITRA   BE0974283153

MITHRA PHARMACEUTICALS S.A.

(MITRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mithra Pharmaceuticals S A : Announces Estelle« Launch in Belgium

10/21/2021 | 01:44am EST

Liege, Belgium, 21 October 2021 - 7:30 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, is very pleased to announce that its novel combined oral contraceptive Estelle® is now available in Belgium. The product is marketed in Belgium by Richter under the brand name Drovelis® and by Ceres Pharma under the brand name Lydisilka®.

Disclaimer

Mithra Pharmaceuticals SA published this content on 21 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2021 05:43:11 UTC.


ę Publicnow 2021
All news about MITHRA PHARMACEUTICALS S.A.
11/30Mayne pharma and mithra announce tga approval of nextstellis oral contraceptive
AQ
11/29MITHRA PHARMACEUTICALS S A : Mayne Pharma and Mithra Announce TGA Approval of Nextstellis«..
PU
11/29MITHRA PHARMACEUTICALS S A : holds today its Investor Day at CDMO
PU
11/29Mayne Pharma Secures Australian Regulatory Approval for Oral Contraceptive
MT
11/10Mithra organizes its Investor Day on November 29, 2021
PU
10/22MITHRA PHARMACEUTICALS S A : Announces Estelle Launch in Belgium
AQ
10/21MITHRA PHARMACEUTICALS S A : Announces Estelle« Launch in Belgium
PU
10/15MITHRA PHARMACEUTICALS S A : The Board of Directors confirms Leon Van Rompay as Mithra's C..
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
More news
Financials
Sales 2021 47,8 M 54,2 M 54,2 M
Net income 2021 -69,0 M -78,1 M -78,1 M
Net Debt 2021 73,3 M 83,0 M 83,0 M
P/E ratio 2021 -13,3x
Yield 2021 -
Capitalization 921 M 1 043 M 1 043 M
EV / Sales 2021 20,8x
EV / Sales 2022 3,44x
Nbr of Employees 300
Free-Float 57,1%
Chart MITHRA PHARMACEUTICALS S.A.
Duration : Period :
Mithra Pharmaceuticals S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MITHRA PHARMACEUTICALS S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 20,90 €
Average target price 35,73 €
Spread / Average Target 71,0%
EPS Revisions
Managers and Directors
Leon van Rompay Chief Executive Officer
Christophe MarÚchal Chief Financial Officer
Ajit S. Shetty Chairman
Graham K. Dixon CSO, Head-Research & Development
Koen Hoffman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MITHRA PHARMACEUTICALS S.A.6.09%1 043
CSL LIMITED9.18%100 628
WUXI BIOLOGICS (CAYMAN) INC.4.77%58 683
SAMSUNG BIOLOGICS CO.,LTD.7.87%50 240
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%33 712